Prudential PLC Buys 31,077 Shares of Halozyme Therapeutics, Inc. $HALO

Prudential PLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 79.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,250 shares of the biopharmaceutical company’s stock after acquiring an additional 31,077 shares during the period. Prudential PLC’s holdings in Halozyme Therapeutics were worth $4,728,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. DLD Asset Management LP grew its holdings in shares of Halozyme Therapeutics by 20.0% during the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after purchasing an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Halozyme Therapeutics by 3.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock worth $152,431,000 after purchasing an additional 63,699 shares in the last quarter. Norges Bank acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $128,201,000. Finally, William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $124,031,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $71.53 on Friday. The firm’s fifty day moving average price is $66.79 and its two-hundred day moving average price is $68.74. The stock has a market cap of $8.48 billion, a PE ratio of 25.73, a PEG ratio of 0.30 and a beta of 0.88. Halozyme Therapeutics, Inc. has a fifty-two week low of $51.06 and a fifty-two week high of $82.22. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company’s revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $69.07, for a total transaction of $690,700.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $53,030,564.60. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total transaction of $599,087.48. Following the completion of the sale, the chief operating officer directly owned 7,055 shares in the company, valued at approximately $477,200.20. This represents a 55.66% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 122,107 shares of company stock valued at $8,254,834. 2.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on HALO shares. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. HC Wainwright boosted their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
• Neutral Sentiment: One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.